ImmuneRegen BioSciences(R) Announces Collaboration With Archimedes Development Limited
26 Agosto 2009 - 9:00AM
Marketwired
ImmuneRegen BioSciences, Inc. ("ImmuneRegen"), a wholly owned
subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), today
announced the execution of a Material Transfer Agreement (MTA) with
Archimedes Development Limited ("Archimedes"), of the UK, an
initial step to enable the companies to investigate possible
synergies between their technology platforms.
"Multiple studies in different model systems have shown that
Homspera® can protect experimental animals and enhance their immune
responses to vaccine-delivered antigens, DNA-encoded viral proteins
or tumor antigens, as well as provide protection in our anthrax and
influenza therapeutic studies," said Hal Siegel, Ph.D.,
ImmuneRegen's Vice President and Chief Scientific Officer. "In
addition to these findings in animals where Homspera has been
administered intranasally as a liquid, inhaled or injected under
the skin, we have shown in laboratory studies that Homspera can
stimulate blood-forming stem cells to produce more white blood cell
precursors, particularly those for granulocytes and macrophages,
mature blood cells which play a significant role in immune
responses. The ability to administer Homspera intranasally is one
we are particularly interested in pursuing. Mucosal vaccination may
be more efficacious than injected vaccines for diseases like
influenza, intestinal diseases and HIV/AIDS. At times, such as
pandemic influenza treatment or vaccination, intranasal
administration might be desirable."
Alan Smith, Ph.D., Archimedes' Vice President of Research &
Development, commented: "We recognize the growing need to improve
the efficacy of available antigens and to facilitate mass
vaccination by means of innovative approaches such as mucosal
administration. As a recognized leader in this field we are excited
to be collaborating with ImmuneRegen to apply our world-leading
expertise and technology platforms to the intranasal delivery of
Homspera."
About Archimedes Development Ltd.
Archimedes Development Limited (ADL) is a subsidiary of
Archimedes Pharma, a fast growing pharmaceutical company focused on
meeting the needs of specialist prescribers in Europe. ADL is
focused on partnering with companies which have compounds which
could benefit from its suite of world-class drug delivery
technologies. These comprise two cutting edge intranasal delivery
technologies ChiSys® and PecSys(TM) as well TARGIT®, which is
designed to deliver drugs to precise regions of the large
intestine. These technologies are able to optimise the profile of a
wide range of therapeutic agents by allowing targeted or controlled
release.
ADL's drug delivery technologies have been validated in a series
of partnerships with pharmaceutical and biotechnology companies. In
the vaccine field, LigoCyte Pharmaceuticals, Inc. is a licensee of
ADL's ChiSys® technology and ADL is the lead partner in the Nasal
Pandemic Influenza Vaccine (NASPANVAC) project funded by the
European Union under the FP7 scheme, which aims to develop an
intranasally delivered vaccine against highly pathogenic strains of
the influenza virus (H5N1 and other H5 and N7 subtypes) using the
ChiSys® platform.
For more information on Archimedes, visit
www.archimedespharma.com.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR
BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage
biotechnology company focused on the research, development and
licensing of Homspera® and its derivatives. Homspera is an adult
stem cell active compound that in study results has been shown to
regenerate and strengthen the immune system and enhance wound
healing. Viprovex®, a derivative of Homspera, is being developed
for potential use against infectious diseases as a stand-alone or
combination therapy and as a vaccine adjuvant. To advance its
mission, the Scottsdale, Arizona based company has forged numerous
study partnerships with industry and academic leaders, including
Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory
Research Institute and Virion Systems. For more information, please
visit www.immuneregen.com.
Statements about ImmuneRegen's future expectations, including
statements about the potential use and scientific results for
ImmuneRegen's drug candidates, science and technology, and all
other statements in this press release other than historical facts,
are "forward-looking statements" within the meaning of Section 27A
of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private
Securities Litigation Reform Act of 1995. ImmuneRegen intends that
such forward-looking statements be subject to the safe harbors
created thereby. These future events may not occur as and when
expected, if at all, and, together with ImmuneRegen's business, are
subject to various risks and uncertainties. ImmuneRegen's actual
results could differ materially from expected results as a result
of a number of factors, including the uncertainties inherent in
research and development collaborations, pre-clinical and clinical
trials and product development programs (including, but not limited
to the fact that future results or research and development efforts
may prove less encouraging than current results or cause side
effects not observed in current pre-clinical trials), the
evaluation of potential opportunities, the level of corporate
expenditures and monies available for further studies, capital
market conditions, and others set forth in ImmuneRegen's periodic
report on Form 10-KSB for the year ended December 31, 2008 as filed
with the Securities and Exchange Commission. There are no
guarantees that any of ImmuneRegen's proposed products will prove
to be commercially successful. ImmuneRegen undertakes no duty to
update forward-looking statements.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: ImmuneRegen BioSciences Inc. John Fermanis Phone:
480-922-3926 E-mail: Email Contact Archimedes Pharma Limited
Michael Clark Phone: +44 118 931 5055 Mary Clark Joey Whineray
Capital MS&L, for media enquiries Phone: +44 20 7307 5330
IR BioSciences (CE) (USOTC:IRBS)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
IR BioSciences (CE) (USOTC:IRBS)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024